Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone
General Info
Time period covered
January, 2006 - December, 2014
Data type
Scientific literature
Keywords
Citation
Journal
J Med Econ
Pages
818-829
Publication year
2019
Suggested citation
Hagiwara M, Panjabi S, Sharma A, Delea TE. Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone. J Med Econ. 2019; 22(8): 818-829.